Deferasirox
Deferasirox is an approved active ingredient.
Pharmaceutical drug
Boxed warning (US label)
RENAL FAILURE, HEPATIC FAILURE, and GASTROINTESTINAL HEMORRHAGE Renal Failure Exjade can cause acute renal failure and death, particularly in patients with comorbidities and those who are in the advanced stages of their hematologic disorders.
What it is used for
- Thalassemia
- Myelodysplastic syndrome
- Iron metabolism disease
- Rare hereditary hemochromatosis
- Beta-thalassemia HBB/LCRB
- Anemia
- Congenital hypoplastic anemia
- Erythroblastopenia
- Hereditary haemochromatosis
- Acute myeloid leukemia
- Myelofibrosis
- Beta thalassemia
- Iron overload
Exjade is an iron chelator indicated for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older.
Exjade is indicated for the treatment of chronic iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) in patients with beta thalassaemia major aged six years and older.
How it works
- Iron chelating agent
Common side effects
The following clinically significant adverse reactions are also discussed in other sections of the labeling: Acute Kidney Injury, Including Acute Renal Failure Requiring Dialysis, and Renal Tubular Toxicity Including Fanconi Syndrome Hepatic Toxicity and Failure GI Hemorrhage Bone Marrow Suppression Hypersensitivity…
Who should not take it
Exjade is contraindicated in patients with: Estimated GFR less than 40 mL/min/1.73 m 2; Poor performance status; High-risk myelodysplastic syndromes; (this patient population was not studied and is not expected to benefit from chelation therapy) Advanced…
Pregnancy and breastfeeding
There are no studies with the use of Exjade in pregnant women to inform drug-associated risks.
Interactions
- Busulfan
- Colestyramine
- Duloxetine
- Melatonin
- Phenobarbital
- Phenytoin
- Repaglinide
- Rifampicin
- Ritonavir
- Tizanidine
Brand names
United States
Exjade · Jadenu · Jadenu Sprinkle
European Union
Deferasirox Accord · Deferasirox Mylan · Exjade
Canada
Alembic-Deferasirox (type J) · Apo-Deferasirox · Apo-Deferasirox (type J) · Auro-Deferasirox (type J) · Exjade · Jadenu · Jamp Deferasirox (type J) · Pms-Deferasirox · Pms-Deferasirox (type J) · Sandoz Deferasirox · Sandoz Deferasirox (type J) · Taro-Deferasirox · Taro-Deferasirox (type J)
Approval status
- US Food and Drug Administration
- prescription · since 2005
- European Medicines Agency
- authorised · since 2006
- Health Canada
- prescription · marketed
- First approval anywhere
- 2005
Codes
- ATC
- V03AC03
- RxNorm CUI
- 614373
- ChEMBL
- CHEMBL550348
- PubChem CID
- 214348
- UNII
- V8G4MOF2V9
- Wikidata
- Q5251502
Frequently asked questions
What is Deferasirox used for?
Deferasirox is used for: Thalassemia, Myelodysplastic syndrome, Iron metabolism disease, Rare hereditary hemochromatosis, Beta-thalassemia HBB/LCRB, Anemia, Congenital hypoplastic anemia, and Erythroblastopenia.
What are the brand names of Deferasirox?
Brand names of Deferasirox include Exjade, Jadenu, Jadenu Sprinkle, Deferasirox Accord, Deferasirox Mylan, Alembic-Deferasirox (type J), Apo-Deferasirox, and Apo-Deferasirox (type J).
Medicines in the same class
Sources and licences
- ChEMBL (CC BY-SA 3.0)
- Wikidata (CC0 1.0)
- openFDA / DailyMed (public domain)
- European Medicines Agency (reuse with acknowledgement)
- Health Canada Drug Product Database (Open Government Licence – Canada)